Abstract
Type 1 diabetes (T1D) is a medical condition that requires constant management, including monitoring of blood glucose levels and administration of insulin. Advancements in diabetes technology have offered methods to reduce the burden on people with T1D. Several hybrid closed-loop systems are commercially available or in clinical trials, each with unique features to improve care for patients with T1D. This article reviews the Omnipod® 5 Automated Glucose Control System Powered by Horizon™ and the safety and efficacy data to support its use in the management of T1D.
Financial & competing interests disclosure
LH Messer has received speaking/consulting honoraria from Tandem Diabetes and DexCom, Inc. and also consults for Clinical Sensors and Capillary Biomedical. Her institution receives research grants from Medtronic, Tandem Diabetes, DexCom, Abbott and Insulet Corp. GP Forlenza conducts research sponsored by Medtronic, Dexcom, Abbott, Insulet, Tandem and Lilly and has served as a speaker/consultant for Medtronic, Dexcom, Insulet, Tandem and Lilly. Erin Cobry receives NIH funding: NIH K12DK094712. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Company review disclosure
In addition to the peer-review process, with the author’s consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the author at their discretion and based on scientific or editorial merit only. The author maintained full control over the manuscript, including content, wording and conclusions.